Aevi Genomic Medicine, LLC, a pioneering entity in the field of genomic medicine, is headquartered in the United States. Founded in 2013, the company has established itself as a leader in developing innovative therapies for rare genetic disorders, particularly focusing on paediatric populations. With a commitment to advancing precision medicine, Aevi Genomic Medicine offers unique solutions that leverage genomic insights to tailor treatments for individual patients. Their proprietary platform integrates advanced genomic technologies, setting them apart in the competitive landscape of biotechnology. Recognised for their significant contributions to the industry, Aevi has achieved notable milestones, including successful clinical trials that underscore their position as a key player in the genomic medicine sector. As they continue to expand their operational reach, Aevi remains dedicated to transforming the lives of patients through cutting-edge genomic therapies.
How does Aevi Genomic Medicine, LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Aevi Genomic Medicine, LLC's score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Aevi Genomic Medicine, LLC, headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. As a result, Aevi Genomic Medicine's climate commitments and initiatives remain unclear, and there is no inherited emissions data from a parent or related organisation. The company may need to establish clear sustainability goals and reporting practices to align with industry standards and enhance its environmental accountability.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Aevi Genomic Medicine, LLC is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.